08/01/22 6:39 PMNasdaq : KRYS clinical triallow floatKrystal Biotech Announces FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical TrialKrystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy,RHEA-AIneutral
08/01/22 7:00 AMNasdaq : KRYS clinical triallow floatKrystal Biotech Receives FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical TrialKrystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy,RHEA-AIneutral
07/06/22 7:00 AMNasdaq : KRYS conferenceslow floatKrystal Biotech to Present at William Blair Biotech Focus Conference 2022Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the William Blair Biotech Focus Conference 2022 taking place in New York from July 12-13. Krish Krishnan,RHEA-AIneutral
06/22/22 7:00 AMNasdaq : KRYS low floatKrystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis BullosaKrystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of B-VEC (beremageneRHEA-AIneutral
06/07/22 7:00 AMNasdaq : KRYS conferenceslow floatKrystal Biotech to Present at Goldman Sachs 43rd Annual Global Healthcare ConferenceKrystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the Goldman Sachs 43 rd Annual Global Healthcare Conference in Rancho Palos Verdes, California. KrishRHEA-AIneutral
05/19/22 7:30 PMNasdaq : KRYS conferencesclinical triallow floatKrystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual MeetingKrystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, is pleased to present new data entitled “GEM-3: phase 3 safety and immunogenicity results of beremagene geperpavec (B-VEC), an investigational, topical geneRHEA-AIneutral
05/09/22 4:15 PMNasdaq : KRYS earningslow floatKrystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational ProgressBiologics License Application for B-VEC remains on track to file in the US in 2Q 2022 and Marketing Authorization in the EU on track to file in 2H 2022 FDA allows dosing at a patient’s home in the Open Label Extension Study of B-VEC for the treatment of DEB Positive Clinical Phase 1 (Pearl-1 Study)RHEA-AIneutral
05/03/22 7:00 AMNasdaq : KRYS conferenceslow floatKrystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare ConferenceKrystal Biotech, Inc. , (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in the Bank of America Merrill Lynch Global HealthcareRHEA-AIneutral
04/11/22 7:00 AMNasdaq : KRYS low floatKrystal Biotech Announces Home Dosing in B-VEC Open Label Extension StudyKrystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies, today announced that it plans to offer patients with dystrophic epidermolysis bullosa (DEB), who are enrolled in the GEM-3 open label extension study, theRHEA-AIneutral
03/28/22 11:00 AMNasdaq : KRYS clinical triallow floatKrystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature MedicineTreatment with B-VEC demonstrated robust functional COL7 expression followed by its assembly into basement membrane-associated anchoring fibrils Treatment with B-VEC improved durable wound closure in patients with recessive dystrophic epidermolysis bullosa (RDEB) compared with placebo with minimalRHEA-AIneutral